Symptoms predicting health-related quality of life in prostate cancer patients treated with localized radiation therapy

Objective Patient-reported health-related quality-of-life (HRQOL) measures can provide guidance for treatment decision making, symptom management, and discharge planning. HRQOL is often influenced by the distress experienced by patients from disease or treatment-related symptoms. This study aimed to identify symptoms that can predict changes in HRQOL in men undergoing external beam radiation therapy (EBRT) for nonmetastatic prostate cancer (NMPC). Methods Fifty-one men with NMPC scheduled for EBRT were assessed at the baseline, at the midpoint of EBRT, and at the end of EBRT. All participants received 38–42 daily doses of EBRT (five times a week), depending on the stage of their disease. Validated questionnaires were administered to evaluate depressive symptoms, urinary and sexual functions, bowel issues, symptom-related distress, fatigue, and HRQOL. Pearson correlations, repeated-measures ANOVA, and multiple regressions examined the relationships among variables. Results Intensification of symptoms and increased symptom-related distress, with a corresponding decline in HRQOL, were observed during EBRT in men with NMPC. Changes in symptoms and symptom distress were associated with changes in HRQOL at the midpoint of EBRT (r=–0.37 to –0.6, P=0.05) and at the end of EBRT (r=–0.3 to –0.47, P=0.01) compared with the baseline. The regression model comprising age, body mass index, Gleason score, T category, androgen-deprivation therapy use, radiation dose received, symptoms (urinary/sexual/bowel problems, fatigue), and overall symptom distress explained 70% of the variance in predicting HRQOL. Urinary problems and fatigue significantly predicted the decline in HRQOL during EBRT. Conclusion Identifying specific symptoms that can influence HRQOL during EBRT for NMPC can provide feasible interventional targets to improve treatment outcomes.

[1]  V. Víctor,et al.  Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications , 2017, Redox biology.

[2]  N. Chattipakorn,et al.  Mitochondrial calcium uniporter blocker effectively prevents brain mitochondrial dysfunction caused by iron overload. , 2013, Life sciences.

[3]  Montse Ferrer,et al.  Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments , 2014, Quality of Life Research.

[4]  R E Slaughter,et al.  The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. , 1998, Oncology nursing forum.

[5]  M. Barry,et al.  THE AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX FOR BENIGN PROSTATIC HYPERPLASIA , 1992, The Journal of urology.

[6]  J. Cappelleri,et al.  The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience , 2005, International Journal of Impotence Research.

[7]  L. Saligan,et al.  Biological Basis for the Clustering of Symptoms. , 2016, Seminars in oncology nursing.

[8]  D. Cella,et al.  Cancer-related fatigue: definitions and clinical subtypes. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  E. Horwitz,et al.  Patient reported outcomes among treatment modalities for prostate cancer. , 2016, The Canadian journal of urology.

[10]  R. Gennis,et al.  Interactions between heme d and heme b595 in quinol oxidase bd from Escherichia coli: a photoselection study using femtosecond spectroscopy. , 2002, Biochemistry.

[11]  J. Nelson,et al.  Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  V. Gebski,et al.  Long Term Patient Reported Urinary Function Following External Beam Radiotherapy for Prostate Cancer. , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

[13]  J. Seidman,et al.  Missense mutations in the BCS1L gene as a cause of the Björnstad syndrome. , 2007, The New England journal of medicine.

[14]  W. Burke,et al.  A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. , 2008, Archives of otolaryngology--head & neck surgery.

[15]  C. Hoppel,et al.  Oxidative phosphorylation and aging , 2006, Ageing Research Reviews.

[16]  J. Armes,et al.  The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature , 2013, Supportive Care in Cancer.

[17]  Jack Clark,et al.  Symptom Indexes to Assess Outcomes of Treatment for Early Prostate Cancer , 2001, Medical care.

[18]  J. Cataldo,et al.  Trajectories and predictors of symptom occurrence, severity, and distress in prostate cancer patients undergoing radiation therapy. , 2012, Journal of pain and symptom management.

[19]  L. Saligan,et al.  Differential expression of genes related to mitochondrial biogenesis and bioenergetics in fatigued prostate cancer men receiving external beam radiation therapy. , 2014, Journal of pain and symptom management.

[20]  A. Zietman,et al.  Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer , 2013, Cancer.

[21]  R. Dess,et al.  Predictors of multidomain decline in health‐related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer , 2017, Cancer.

[22]  K. Herfarth,et al.  Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial. , 2016, International journal of radiation oncology, biology, physics.

[23]  E. Shaw,et al.  Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Saligan,et al.  The role of TRAIL in fatigue induced by repeated stress from radiotherapy. , 2017, Journal of psychiatric research.

[25]  L. Saligan,et al.  Mitochondria-Related Gene Expression Changes Are Associated With Fatigue in Patients With Nonmetastatic Prostate Cancer Receiving External Beam Radiation Therapy , 2013, Cancer nursing.

[26]  T. Brand,et al.  A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy. , 2017, Urologic oncology.

[27]  B. Bokhour,et al.  Measuring Patients' Perceptions of the Outcomes of Treatment for Early Prostate Cancer , 2003, Medical care.

[28]  E. Berthelet,et al.  Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy. , 2006, The Canadian journal of urology.

[29]  R. Lill,et al.  The Essential Role of Mitochondria in the Biogenesis of Cellular Iron-Sulfur Proteins , 1999, Biological chemistry.

[30]  I. Osterloh,et al.  Relationship between patient self-assessment of erectile dysfunction and the sexual health inventory for men. , 2001, Clinical therapeutics.

[31]  J. Chipuk,et al.  Mitochondrial Fission in Human Diseases. , 2017, Handbook of experimental pharmacology.

[32]  E. Horwitz,et al.  Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. , 2016, Cancer treatment reviews.

[33]  L. Saligan,et al.  The Association of IFI27 Expression and Fatigue Intensification during Localized Radiation Therapy: Implication of a Para-Inflammatory Bystander Response , 2013, International journal of molecular sciences.

[34]  C. Hoppel,et al.  Association between Mitochondrial Bioenergetics and Radiation- Related Fatigue: A Possible Mechanism and Novel Target , 2015 .

[35]  M. Q. Almerie,et al.  Measuring the individual quality of life of patients with prostate cancer , 2008, Prostate Cancer and Prostatic Diseases.

[36]  E. P. Choi,et al.  Psychometric properties of Functional Assessment of Cancer Therapy-Prostate (FACT-P) in Chinese patients with prostate cancer , 2015, Quality of Life Research.

[37]  H. Matar,et al.  Quality of life in patients with prostate cancer: development and application of a hybrid assessment method , 2009, Prostate Cancer and Prostatic Diseases.

[38]  Enrique J. deAndrés-Galiana,et al.  Relationship of Mitochondrial Enzymes to Fatigue Intensity in Men With Prostate Cancer Receiving External Beam Radiation Therapy , 2016, Biological research for nursing.

[39]  K. Pienta,et al.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.

[40]  E. Horwitz,et al.  Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. , 2015, International journal of radiation oncology, biology, physics.

[41]  K. Blomberg,et al.  Early detection and management of symptoms using an interactive smartphone application (Interaktor) during radiotherapy for prostate cancer , 2017, Supportive Care in Cancer.